Patents by Inventor Yukinori Take
Yukinori Take has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066040Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.Type: ApplicationFiled: July 19, 2023Publication date: February 29, 2024Inventors: Mark MANFREDI, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
-
Patent number: 11840530Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: GrantFiled: March 15, 2021Date of Patent: December 12, 2023Assignee: AskAt Inc.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
-
Publication number: 20220073510Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: ApplicationFiled: March 15, 2021Publication date: March 10, 2022Applicant: AskAt Inc.Inventors: Yukinori TAKE, Shinichi KOIZUMI, Takako OKUMURA, Kazuhiko NONOMURA
-
Publication number: 20210290641Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.Type: ApplicationFiled: March 1, 2021Publication date: September 23, 2021Inventors: Mark Manfredi, Jeffrey ECSEDY, Atsushi NAGAHISA, Yukinori TAKE, Takako OKUMURA
-
Patent number: 10973834Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.Type: GrantFiled: April 16, 2019Date of Patent: April 13, 2021Assignees: Arrys Therapeutics, Inc., AskAt Inc.Inventors: Mark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
-
Patent number: 10947235Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: GrantFiled: February 27, 2020Date of Patent: March 16, 2021Assignee: AskAt Inc.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
-
Publication number: 20200188367Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: ApplicationFiled: February 27, 2020Publication date: June 18, 2020Applicant: AskAt Inc.Inventors: Yukinori TAKE, Shinichi KOIZUMI, Takako OKUMURA, Kazuhiko NONOMURA
-
Patent number: 10611761Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: GrantFiled: May 23, 2017Date of Patent: April 7, 2020Assignee: AskAt Inc.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
-
Publication number: 20190314390Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.Type: ApplicationFiled: April 16, 2019Publication date: October 17, 2019Inventors: Mark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
-
Publication number: 20170253595Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (VI) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: ApplicationFiled: May 23, 2017Publication date: September 7, 2017Applicant: AskAt Inc.Inventors: Yukinori TAKE, Shinichi KOIZUMI, Takako OKUMURA, Kazuhiko NONOMURA
-
Patent number: 9688674Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: GrantFiled: November 19, 2014Date of Patent: June 27, 2017Assignee: AskAt Inc.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
-
Publication number: 20150111920Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: ApplicationFiled: November 19, 2014Publication date: April 23, 2015Inventors: Yukinori TAKE, Shinichi KOIZUMI, Takako OKUMURA, Kazuhiko NONOMURA
-
Patent number: 8980922Abstract: This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof with 5-HT4 agonistic activities, which is useful in the treatment of dementia. This invention also relates to a pharmaceutical composition for the treatment of dementia which comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of dementia in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 14, 2011Date of Patent: March 17, 2015Assignee: Raqualia Pharma Inc.Inventors: Hiroyuki Ohshiro, Akiyoshi Fujiuchi, Yukinori Take
-
Patent number: 8921391Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: GrantFiled: April 22, 2010Date of Patent: December 30, 2014Assignee: RaQualia Pharma Inc.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
-
Publication number: 20120322826Abstract: This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof with 5-HT4 agonistic activities, which is useful in the treatment of dementia. This invention also relates to a pharmaceutical composition for the treatment of dementia which comprises a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of dementia in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 14, 2011Publication date: December 20, 2012Applicant: RQUALIA PHAMRA INC.Inventors: Hiroyuki Ohshiro, Akiyoshi Fujiuchi, Yukinori Take
-
Publication number: 20120088723Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.Type: ApplicationFiled: April 22, 2010Publication date: April 12, 2012Applicant: RAQUALIA PHARMA INC.Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura